Azitra, Inc. Merges with Akari Therapeutics plc
Ticker: AZTR · Form: 8-K · Filed: Jul 3, 2024 · CIK: 1701478
Sentiment: neutral
Topics: merger, acquisition, corporate-action
Related Tickers: AKTX
TL;DR
Azitra is now part of Akari Therapeutics as of June 27, 2024.
AI Summary
On June 27, 2024, Azitra, Inc. filed an 8-K report detailing several key events. The company announced the closing of its previously disclosed merger with Akari Therapeutics plc, effective June 27, 2024. This merger resulted in Azitra stockholders receiving shares of Akari Therapeutics plc. The filing also includes information on amendments to Azitra's articles of incorporation and bylaws, and submission of matters to a vote of security holders.
Why It Matters
This 8-K filing signifies the completion of Azitra's merger with Akari Therapeutics, changing the corporate structure and ownership for Azitra's stockholders.
Risk Assessment
Risk Level: medium — Mergers and acquisitions inherently carry risks related to integration, regulatory approval, and market reception.
Key Players & Entities
- Azitra, Inc. (company) — Registrant
- Akari Therapeutics plc (company) — Merging entity
- June 27, 2024 (date) — Effective date of merger
FAQ
What was the effective date of the merger between Azitra, Inc. and Akari Therapeutics plc?
The merger was effective as of June 27, 2024.
What did Azitra, Inc. stockholders receive as a result of the merger?
Azitra stockholders received shares of Akari Therapeutics plc.
What type of SEC filing is this report?
This is a Form 8-K, a Current Report.
What are the principal executive offices of Azitra, Inc.?
The principal executive offices are located at 21 Business Park Drive, Branford, CT 06405.
What is the IRS Employer Identification Number for Azitra, Inc.?
The IRS Employer Identification Number is 46-4478536.
Filing Stats: 594 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-07-03 16:05:17
Key Financial Figures
- $0.0001 — ch registered Common Stock: Par value $0.0001 AZTR NYSE American Indicate by ch
Filing Documents
- form8-k.htm (8-K) — 43KB
- 0001493152-24-026211.txt ( ) — 214KB
- aztr-20240627.xsd (EX-101.SCH) — 3KB
- aztr-20240627_lab.xml (EX-101.LAB) — 33KB
- aztr-20240627_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AZITRA , INC. Dated: July 3, 2024 /s/ Francisco D. Salva Francisco D. Salva Chief Executive Officer